BOONTON, N.J., Oct. 26, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), announced today that research into the pharmacokinetics of an oral formulation of leuprolide (Ovarest®) utilizing Enteris' proprietary Peptelligence® platform was highlighted in an oral presentation at the ASRM 2022 Scientific Congress & Expo in Anaheim, Calif.
DALLAS, Oct. 10 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that its wholly-owned subsidiary, Enteris BioPharma, received a $5 million clinical progression milestone payment from Cara Therapeutics (Nasdaq: CARA) related to the license agreement for the Peptelligence® oral formulation technology utilized in Oral KORSUVA™, the oral formulation of Cara's first-in-class KOR agonist, CR845/difelikefalin. Enteris is entitled to retain $2.5 million of this payment per the contractual splits agreed to in the Enteris acquisition agreement.
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a...
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a...
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a...
BOONTON, N.J., May 26, 2022 /PRNewswire/ -- Enteris BioPharma, Inc. gave plush animals a dose of personality as they created a dozen stuffed teddy bears for Ronald McDonald House Charities to help comfort sick children as they undergo medical treatment.
BOONTON, N.J., May 4, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), announced today that the company will participate in and exhibit at CPhI North America 2022 being held May 17-19, 2022 in Philadelphia (Booth 1708).
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a...